Literature DB >> 14599277

Effect of the fragile X status categories and the fragile X mental retardation protein levels on executive functioning in males and females with fragile X.

Danuta Z Loesch1, Quang M Bui2, Jim Grigsby3, Emma Butler1, Jennifer Epstein4, Richard M Huggins2, Annette K Taylor5, Randi J Hagerman6.   

Abstract

The effects of a fragile X disorder on executive function impairment were assessed in 144 extended families, which included individuals with fragile X premutation and full mutation and their relatives without fragile X. A modification of the maximum-likelihood estimators for pedigree data, as well as ordinal logistic regression, were used in data analysis. The most outstanding deficit, occurring especially in males, involved impaired capacity to use an intention to regulate purposeful behavior. This deficit occurred independently of general cognitive impairment but was related to depletion of fragile X mental retardation 1 gene protein product. The other executive function deficits were accounted for by the general cognitive impairment. Possible mechanisms of the effect of fragile X premutation on impairments of executive functioning are considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14599277     DOI: 10.1037/0894-4105.17.4.646

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  40 in total

Review 1.  The state of synapses in fragile X syndrome.

Authors:  Brad E Pfeiffer; Kimberly M Huber
Journal:  Neuroscientist       Date:  2009-03-26       Impact factor: 7.519

2.  Clinically significant psychiatric symptoms among male carriers of the fragile X premutation, with and without FXTAS, and the mediating influence of executive functioning.

Authors:  Jim Grigsby; Angela G Brega; Rachael E Bennett; James A Bourgeois; Andreea L Seritan; Glenn K Goodrich; Randi J Hagerman
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

3.  A mouse model of the fragile X premutation: effects on behavior, dendrite morphology, and regional rates of cerebral protein synthesis.

Authors:  Mei Qin; Ali Entezam; Karen Usdin; Tianjian Huang; Zhong-Hua Liu; Gloria E Hoffman; Carolyn B Smith
Journal:  Neurobiol Dis       Date:  2011-01-08       Impact factor: 5.996

Review 4.  Comprehensive neurocognitive endophenotyping strategies for mouse models of genetic disorders.

Authors:  Michael R Hunsaker
Journal:  Prog Neurobiol       Date:  2012-01-13       Impact factor: 11.685

5.  Executive Dysfunction in Female FMR1 Premutation Carriers.

Authors:  Annie L Shelton; Kim M Cornish; Claudine M Kraan; Reymundo Lozano; Minh Bui; Joanne Fielding
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

6.  Impaired activity-dependent FMRP translation and enhanced mGluR-dependent LTD in Fragile X premutation mice.

Authors:  Adam J Iliff; Abigail J Renoux; Amy Krans; Karen Usdin; Michael A Sutton; Peter K Todd
Journal:  Hum Mol Genet       Date:  2012-12-18       Impact factor: 6.150

Review 7.  Gene, brain, and behavior relationships in fragile X syndrome: evidence from neuroimaging studies.

Authors:  Amy A Lightbody; Allan L Reiss
Journal:  Dev Disabil Res Rev       Date:  2009

8.  Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers.

Authors:  P E Adams; J S Adams; D V Nguyen; D Hessl; J A Brunberg; F Tassone; W Zhang; K Koldewyn; S M Rivera; J Grigsby; L Zhang; C Decarli; P J Hagerman; R J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-04-05       Impact factor: 3.568

9.  Fragile X and autism: Intertwined at the molecular level leading to targeted treatments.

Authors:  Randi Hagerman; Gry Hoem; Paul Hagerman
Journal:  Mol Autism       Date:  2010-09-21       Impact factor: 7.509

10.  Phenotypes of hypofrontality in older female fragile X premutation carriers.

Authors:  Jin-Chen Yang; Christa Simon; Yu-Qiong Niu; Mark Bogost; Andrea Schneider; Flora Tassone; Andreea Seritan; Jim Grigsby; Paul J Hagerman; Randi J Hagerman; John M Olichney
Journal:  Ann Neurol       Date:  2013-08       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.